aIIV-B
Trade name: HepliSav B
Vaccineexperimental
Clinical trial activity
3 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 25, 2022 (NCT05501561)
Timeline
Indications
Mechanism of action
- Hepatitis B virusImmunity, active
Hepatitis B virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06513286 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2024 | Ludwig Maximilians University |
| NCT05727267 | Phase 1 | Jan 31, 2024 | Fraunhofer, German Center for Infection Research, Helmholtz Centre for Infection Research, Ludwig Maximilians University, Monipol Deutschland GmbH, University of Hamburg |
| NCT05501561 | Phase 2 | Aug 25, 2022 | CSL Behring |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ludwig Maximilians University | Academic/Hospital | 2 | 1 | 2 | 2024 |
| CSL Behring | For profit | 1 | 1 | 1 | 2022 |
| Fraunhofer | For profit | 1 | 0 | 1 | 2024 |
| German Center for Infection Research | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Helmholtz Centre for Infection Research | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Monipol Deutschland GmbH | For profit | 1 | 0 | 1 | 2024 |
| University of Hamburg | Academic/Hospital | 1 | 1 | 1 | 2024 |
7 organizations
Page 1 / 1